Keyword: Mavyret (glecaprevir and pibrentasvir)
Gilead Sciences launches its first campaign for hepatitis C treatment Epclusa, highlighting its versatility across different strains of the disease.
Joining the list of top 10 pharma TV spenders were a group of new brands including Aimovig, Mavyret and Truvada.
AbbVie is pushing its time-to-cure advantage in new ads for hepatitis C treatment Mavyret that emphasize a cure “in only 8 weeks.”
New phase 3b data showed that, with just eight weeks of treatment, Mavyret could cure HCV patients with compensated cirrhosis.
AbbVie inked a deal with the Medicines Patent Pool to boost access to hep C drug Mavyret in nearly 100 low- and middle-income countries and territories.
AbbVie CFO Bill Chase will retire in 2019 after helming finance since the company's birth in 2013. He'll be replaced by controller Robert Michael.
Gilead's hepatitis C sales have eroded big-time, and the company is taking an unusual new tack that might deliver its drugs to new patients.
It’s that time of year again—the time when lead PBM Express Scripts ignites pharma’s ire with a brand-new list of formulary exclusions.
AbbVie is hitting the road this month to spur veterans toward hepatitis C testing in a cross-country bus tour with the American Legion.
AbbVie is bracing for European biosimilar competition to Humira, but the drug is still continuing its upward trajectory.